Noah Stansfield

Bhagirathbhai R. Dholaria, MD, an associate professor of medicine in malignant hematology & stem cell transplantation at Vanderbilt University Medical Center, discussed interim data from the phase 1/1b clinical trial evaluating Poseida's CAR-T.

The chief executive officer of ASGCT discussed likely future trends extrapolated from the organization’s Q3 Landscape Report.

Georg Schett, MD, vice president research and chair of internal medicine at the University of Erlangen – Nuremberg discussed findings from 2 early studies of CD19 CAR T-cell therapy.

All 3 patients who received the high dose showed stabilization of motor function, as assessed by the 34-point North Star Ambulatory Assessment, at 1 to 2 years posttreatment. Notably, 1 of these patients showed improvement with a maximum score of 34 recorded 12 months after dosing. This improvement was later confirmed at the 18 month time point. By contrast, untreated patients followed in a natural history studied being carried out by Genethon showed a rapid decline in motor function over the same course of time.

David Barrett, JD, the chief executive officer of ASGCT, discussed the latest trends in the field of cell and gene therapy.

The FDA has approved StemCyte's Regenecyte, an allogeneic hematopoietic stem cell therapy derived from human umbilical cord blood, for use in

The patient's dosing took place at the University of California, San Francisco, although the multicenter study is expected to eventually dose patients at other locations in the United States, United Kingdom, and Europe. The patient received a dose of 3x10

David Barrett, JD, the chief executive officer of ASGCT, discussed likely future trends extrapolated from the organization's Q3 Landscape Report.

Cabaletta Bio's CABA-201, an investigational CD19-directed chimeric antigen receptor T-cell (CAR-T) therapy intended to treat various indications, has

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.